CNSide® Featured at BioHouston’s October Life Science Event

by | Oct 14, 2025 | LM

Last week, CNSide® Medical Director Jonathan Stein, PhD, HCLD(ABB) presented at BioHouston’s October Life Science event — joining Houston’s growing network of researchers, entrepreneurs, and clinicians driving the future of biotech innovation.

The discussion centered on how emerging diagnostic technologies are reshaping cancer research, treatment monitoring, and collaboration across Houston’s rapidly expanding life sciences ecosystem.

Why This Matters: Diagnostics Power the Future of Targeted Therapy

At Plus Therapeutics, innovation doesn’t stop at drug development — it extends to how we detect, monitor, and measure disease within the central nervous system (CNS).

Through CNSide Diagnostics, a wholly owned subsidiary of Plus Therapeutics, we’re developing advanced cerebrospinal fluid (CSF) assays designed to quantify tumor cells and track response to therapy in patients with leptomeningeal metastases (LM).

This precision diagnostic platform directly supports our ReSPECT-LM clinical trial — which evaluates REYOBIQ™ (rhenium-186 nanoliposomes), an investigational radiotherapeutic delivered directly to the CSF to treat LM.

By pairing CNSide’s analytical insight with the ReSPECT-LM therapeutic program, Plus Therapeutics aims to close the loop between diagnosis, treatment, and measurable outcomes — helping clinicians better identify eligible patients, assess therapy effectiveness, and improve personalized care for those with CNS malignancies.

CNSide’s Role in the Future of CNS Oncology

Events like BioHouston’s October gathering highlight why Houston is emerging as a national hub for neuro-oncology and precision medicine. Supported by organizations such as the Texas Medical Center and the Cancer Prevention and Research Institute of Texas (CPRIT), the region fosters collaboration between academic institutions, biotech innovators, and clinical researchers working to transform CNS cancer care.

CNSide and Plus Therapeutics are proud to be part of this ecosystem — uniting diagnostics and therapeutics to bring clarity, precision, and hope to patients facing one of the most complex forms of cancer.

Learn More

Together, these efforts represent the next generation of theranostics — where diagnostics and targeted therapy work hand-in-hand to advance outcomes in leptomeningeal metastases and beyond.